Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial.

From the primary efficacy analysis in the complete cases cohort at 180 days, patients who had riluzole had 1.8 (95% confidence interval [CI]: -2.5-6.1) higher average gain in UEM scores when compared with placebo, which did not reach statistical significance (16.4 vs. 14.7; Table 2 ).

also in 111,027 other papers